Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 357

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Novel combination of serum microRNA for detecting breast cancer in the early stage

Open access
Shimomura, Akihiko, Shiino, Sho, Kawauchi, Junpei, Takizawa, Satoko, Sakamoto, Hiromi, Matsuzaki, Juntaro, Ono, Makiko, Takeshita, Fumitaka, Niida, Shumpei, Shimizu, Chikako, Fujiwara, Yasuhiro, Kinoshita, Takayuki, Tamura, Kenji, Ochiya, Takahiro·2016·Cancer Science

Abstract

MicroRNA (miRNA), which are stably present in serum, have been reported to be potentially useful for detecting cancer. In the present study, we examined the expression profiles of serum miRNA in several large cohorts to identify novel miRNA that can be used to detect early stage breast cancer. We comprehensively evaluated the serum miRNA expression profiles using highly sensitive microarray analysis. A total of 1280 serum samples of breast cancer patients stored in the National Cancer Center Biobank were used. In addition, 2836 serum samples were obtained from non‐cancer controls, 451 from patients with other types of cancers, and 63 from patients with non‐breast benign diseases. The samples were divided into a training cohort including non‐cancer controls, other cancers and breast cancer, and a test cohort including non‐cancer controls and breast cancer. The training cohort was used to identify a combination of miRNA that could detect breast cancer, and the test cohort was used to validate that combination. miRNA expressions were compared between patients with breast cancer and non‐breast cancer, and a combination of five miRNA (miR‐1246, miR‐1307‐3p, miR‐4634, miR‐6861‐5p and miR‐6875‐5p) was found to be able to detect breast cancer. This combination had a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% for breast cancer in the test cohort. In addition, this combination could detect early stage breast cancer (sensitivity of 98.0% for Tis).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cas.12880

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 357

Metadata

Authors
Shimomura, A., Shiino, S., Kawauchi, J., Takizawa, S., Sakamoto, H., Matsuzaki, J., Ono, M., Takeshita, F., Niida, S., Shimizu, C., Fujiwara, Y., Kinoshita, T., Tamura, K., & Ochiya, T.
Venue
Cancer Science
Publisher
Wiley
Published
2016-03
Volume
107
Issue
3
Pages
326-334
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W2224319365
Cited by
357
References
25
FWCI
12.25
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel combination of serum microRNA for detecting breast cancer in the early stage. https://app.cochat.ai/papers/10.1111/cas.12880
The paper
Shimomura, A., Shiino, S., Kawauchi, J., Takizawa, S., Sakamoto, H., Matsuzaki, J., Ono, M., Takeshita, F., Niida, S., Shimizu, C., Fujiwara, Y., Kinoshita, T., Tamura, K., & Ochiya, T. (2016). Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Science. https://doi.org/10.1111/cas.12880

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.